ReviewBiomedicines2023
Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 60 citations in OpenAlex.
- Circulating microRNA panels in subjects with metabolic dysfunction-associated steatotic liver disease after following a 2-year dietary intervention.Journal of endocrinological investigation · 2025Trial
- Lubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.Alimentary pharmacology & therapeutics · 2025Trial
- Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation.Gut microbes · 2026Article
- Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease.Digestive diseases and sciences · 2026Article
- Risk assessment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-related liver disease: current approaches and future directions.Clinical and molecular hepatology · 2026Review
- Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol-related liver disease in human immunodeficiency virus.World journal of virology · 2026Review
- Longitudinal Inpatient Trajectories After Splenic Artery Embolization in Cirrhosis: Real-World Evidence from Kazakhstan.Journal of clinical medicine · 2026Article
- Lactobacillus Plantarum Q180 Attenuates Hepatic Lipid Accumulation and Regulates Energy Metabolism in High-Fat Diet-Induced Obese Mice.Probiotics and antimicrobial proteins · 2026Article
- Calpain-4 Knockdown Modulates Cholesterol Metabolism and LXRα Nuclear Localization in Experimental Alcohol-Related Liver Disease.Alcohol, clinical & experimental research · 2026Article
- An Apparent Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with High Levels of Estimated Small Dense LDL Cholesterol in a Japanese Population.Journal of atherosclerosis and thrombosis · 2026Article
- Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation.Hepatology communications · 2026Article
- Research advances on gut microbiota dysbiosis and chronic liver diseases: a review.Frontiers in medicine · 2026Review
- Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease.Research square · 2025Article
- Calpain-4 Knockdown Modulates Cholesterol Metabolism and LXRα Nuclear Localization in Alcohol-Related Liver Disease.bioRxiv : the preprint server for biology · 2025Article
- Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial.Journal of Taibah University Medical Sciences · 2025Article
- Deep Learning Reveals Liver MRI Features Associated With PNPLA3 I148M in Steatotic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Is an Independent Risk Factor for the Development of Ischemic Heart Disease - A 10-Year Cohort Study.Circulation reports · 2025Article
- The AKAP12-PKA axis regulates lipid homeostasis during alcohol-associated liver disease.Signal transduction and targeted therapy · 2025Article
- Prevalence and longitudinal effects on mortality associated with spectrum of alcohol intake in steatotic liver disease: a United States population study.Hepatobiliary surgery and nutrition · 2025Article
- Carotenoids Improve Obesity and Fatty Liver Disease via Gut Microbiota: A Narrative Review.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), both of them accounting for fatty liver disease (FLD), are among the most common chronic liver diseases globally, contributing to substantial public health burden. Both NAFLD and ALD share a similar picture of clinical presentation yet may have differences in prognosis and treatment, which renders early and accurate diagnosis difficult but necessary. While NAFLD is the fastest increasing chronic liver disease, the prevalence of ALD has seemingly remained stable in recent years. Lately, the term steatotic liver disease (SLD) has been introduced, replacing FLD to reduce stigma. SLD represents an overarching term to primarily comprise metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), as well as alcohol-related liver disease (ALD), and MetALD, defined as a continuum across which the contribution of MASLD and ALD varies. The present review discusses current knowledge on common denominators of NAFLD/MASLD and ALD in order to highlight clinical and research needs to improve our understanding of SLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.